Menu
Recruiting NCT07312474

Epidemiological, Clinical and Biological Characteristics of Human Anaplasmosis Cases in Alsace

Observational Human Anaplasmosis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Human Anaplasmosis. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Epidemiological, Clinical and Biological Characteristics of Human Anaplasmosis Cases in Alsace: a Retrospective and Multicenter Study

Overview

Anaplasmosis is a bacterial infection caused by the intracellular bacterium Anaplasma phagocytophilum and transmitted by ticks. This bacterium is present in approximately 1% of ticks in Alsace. This infection is responsible for clinical manifestations that are most often mild, including fever, headache, and myalgia, occurring 2 to 3 weeks after a tick bite. However, this infection can be accompanied by potentially serious or even fatal complications, including severe cytopenias, acute respiratory distress syndrome, septic shock, severe neurological disorders, hemorrhagic manifestations, macrophage activation syndrome, and multiple organ failure. Mortality is variable and appears to be higher in American studies, where it is around 4%. Treatment is well-established and relies on doxycycline, which is highly effective. Although a few cases have been described in France, these are mostly isolated cases or short series of cases, whereas Belgium, Poland, and Slovenia have reported numerous cases. Thus, there is a lack of data on French cases, and given that Alsace is in a region with a high prevalence of tick-borne diseases, data is needed to better understand the epidemiology and to better identify suspected cases in order to provide appropriate care.

Primary outcome measures

  • Mortality of cases of human anaplasmosis in Alsace [Time frame: Up to 12 years]

Eligibility criteria

Inclusion criteria

  • Adult subjct (≥18 years)
  • Presenting with a PCR-confirmed infection of Anaplasma

Exclusion criteria

\- Refusal to participate in the study

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Study design

Observational model
Case-only

Study locations

France · 1 center
  • Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France — Strasbourg

Identifiers

NCT: NCT07312474 · 9458

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗